Health Effects of Soccer Training in Men With Prostate Cancer Receiving Androgen Deprivation Therapy

April 16, 2014 updated by: Jacob Uth, University of Copenhagen

A Randomized Controlled Clinical Trial on the Effects of Recreational Soccer Training in Men With Prostate Cancer Receiving Androgen Deprivation Therapy: The FC Prostate Study

Androgen Deprivation Therapy (ADT) is standard treatment for locally advanced or advanced Prostate Cancer (PC).

The musculoskeletal toxicity associated with ADT is well established, leading to a decrease in muscle mass, increased fat percentage, weight gain, sexual dysfunction and increased risk of depression, fatigue, diabetes, cardiovascular disease and reduced quality of life.

Numerous studies have shown an association between physical activity, physical capacity and quality of life in cancer patients and recent epidemiological research suggest that regular, moderate-intensity physical activity may have a positive effect on survival in men with prostate cancer.

Within exercise physiology there is new evidence pointing to recreational soccer as a unique form of intermittent exercise that effectively stimulates aerobic and anaerobic energy delivery systems, leading to beneficial musculoskeletal, metabolic and cardiovascular adaptations of importance for health.

It is our overall hypothesis that 12 weeks of recreational soccer training 2-3 times per week will improve the health profile of PC patients receiving ADT treatment.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Actual)

57

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Denmark
      • Copenhagen, Denmark, 2100
        • University of Copenhagen, Centre of Integrated Rehabilitation of Cancer Patients

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 75 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

Male

Description

Inclusion Criteria:

- Patients with locally advanced or advanced prostate cancer being treated with androgen deprivation therapy (S-testosterone < 1.7) for at least 6 months at the time of inclusion

Exclusion Criteria:

  • WHO performance level above 1,symptomatic cardiovascular disorders, osteoporosis (T-score below -2.5)

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Supportive Care
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
No Intervention: Control group
Usual care
Active Comparator: Soccer Training
12 weeks of soccer training. (2 times per week for the first 8 weeks and 3 times per week in the last 4 weeks. Training will consist of 15 minutes warm-up and 2 x 15 minutes matches for the first 4 weeks and of 15 minutes warm-up and 3 x 15 minutes matches for the last 8 weeks). After 12 weeks assessments participants in the intervention group will continue bi-weekly supervised training for additional 20 weeks at the end of which tests will be repeated.
Behavioral: Soccer training

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Baseline to post intervention (12 weeks) and follow-up (32 weeks) change in Body Composition.
Time Frame: Change from baseline to post intervention (12 weeks) and follow-up (32 weeks)
Changes in body composition assessed by Dual-energy X-ray absorptiometry(DXA)scan
Change from baseline to post intervention (12 weeks) and follow-up (32 weeks)

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Bone Mineral Density
Time Frame: Change from baseline to post intervention (12 weeks) and follow-up (32 weeks)
Change from baseline to post intervention (12 weeks) and follow-up (32 weeks)
Cardiorespiratory fitness (Vo2 peak)
Time Frame: Change from baseline to post intervention (12 weeks) and follow-up (32 weeks)
Change in maximal oxygen consumption (Vo2 peak) assessed directly during an incremental test on a cycle ergometer from baseline to post-intervention (12 weeks) and follow-up (32 weeks).
Change from baseline to post intervention (12 weeks) and follow-up (32 weeks)
Patient reported outcomes
Time Frame: Change from baseline to post intervention (12 weeks) and follow-up (32 weeks)
Changes in Psychological distress (Hospital Anxiety and Depression Scale, HADS), Quality of Life (EORTC QLQ C-30), general well-being (SF-36), disease specific symptoms and side-effects (EORTC PR-25)from baseline to post-intervention (12 weeks) and follow-up (32 weeks)
Change from baseline to post intervention (12 weeks) and follow-up (32 weeks)
Heart function
Time Frame: Change from baseline to post intervention (12 weeks) and follow-up (32 weeks)
Changes in Heart function measured by Echocardiography from baseline to post-intervention (12 weeks) and follow-up (32 weeks)
Change from baseline to post intervention (12 weeks) and follow-up (32 weeks)
Glucose tolerance
Time Frame: Change from baseline to post intervention (12 weeks) and follow-up (32 weeks)
Oral Glucose Tolerance Test
Change from baseline to post intervention (12 weeks) and follow-up (32 weeks)
Postural Balance
Time Frame: Change from baseline to post intervention (12 weeks) and follow-up (32 weeks)
Assessed standing on a force platform with feet in bilateral, unilateral and tandem position. Additionally assessed with a modified Flamingo balance test.
Change from baseline to post intervention (12 weeks) and follow-up (32 weeks)
Physical function
Time Frame: Change from baseline to post intervention (12 weeks) and follow-up (32 weeks)
Physical function will be assessed with sit to stand test (30s), stair climbing test and Counter Movement Jump (jump height)
Change from baseline to post intervention (12 weeks) and follow-up (32 weeks)
Hip to waist ratio
Time Frame: Change from baseline to post intervention (12 weeks) and follow-up (32 weeks)
Hip and waist circumference will be measured and the hip to waist ratio will be calculated
Change from baseline to post intervention (12 weeks) and follow-up (32 weeks)
Muscle Strength
Time Frame: Change from baseline to post intervention (12 weeks) and follow-up (32 weeks)
Muscle strength will be assessed with the 1Repetition Maximum test for knee extensors
Change from baseline to post intervention (12 weeks) and follow-up (32 weeks)
Blood markers
Time Frame: Change from baseline to post intervention (12 weeks) and follow-up (32 weeks)
Markers of inflammation and bone metabolism will be obtained after overnight fasting
Change from baseline to post intervention (12 weeks) and follow-up (32 weeks)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

University of Copenhagen

Collaborators

Novo Nordisk A/S
Danish Cancer Society
TrygFonden, Denmark
Beckett Foundation

Investigators

  • Principal Investigator: Mikael Rørth, Professor, University of Copenhagen

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

March 1, 2012

Primary Completion (Actual)

December 1, 2013

Study Completion (Actual)

December 1, 2013

Study Registration Dates

First Submitted

October 17, 2012

First Submitted That Met QC Criteria

October 18, 2012

First Posted (Estimate)

October 22, 2012

Study Record Updates

Last Update Posted (Estimate)

April 21, 2014

Last Update Submitted That Met QC Criteria

April 16, 2014

Last Verified

April 1, 2014

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • CIRE-04

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Prostatic Neoplasms

Clinical Trials on Soccer training

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Angola

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe